Toripalimab plus chemo with or without allergy medicine for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding an allergy medicine (H1 receptor antagonist) to the usual combination of immunotherapy (toripalimab) and chemotherapy helps treat lung cancer that can be removed surgically. The goal is to shrink the tumor before surgery and reduce the chance of it coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage II or III non-small cell lung cancer that can be removed with surgery.
- You have not had any prior chemotherapy, radiation, or other cancer treatments for this lung cancer.
- You are in good general health, able to walk and take care of yourself (ECOG score 0-1).
- Your blood counts, liver, kidney, and thyroid function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests a combination of the immunotherapy drug tislelizumab, standard chemotherapy, and an antihistamine (diphenhydramine) as a first treatment for advanced non-small cell lung cancer. The antihistamine may help reduce side effects or improve the immune response.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.